Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/31/23
End: 06/30/27
Due: 06/30/28
Phase: N/A
Priority: Normal
Start: 12/31/16
End: 12/31/18
Due: 12/31/19
Phase: N/A
Priority: Normal
Start: 11/11/19
End: 06/28/21
Due: 06/28/22
Phase: N/A
Priority: Normal
Start: 04/01/20
End: 01/01/23
Due: 01/01/24
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | NCT05864144 | Sensei Biotherapeutics, Inc. | user2@example.com | None | 2023-05-31 | 2027-06-30 | 2028-06-30 | - | - | 2025-07-14 |
| Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients | NCT03120832 | Sensei Biotherapeutics, Inc. | user2@example.com | None | 2016-12-31 | 2018-12-31 | 2019-12-31 | - | - | 2025-07-14 |
| Addition of SNS-301 to Checkpoint Inhibitor Treatment in Metastatic/Recurrent SCCHN | NCT04034225 | Sensei Biotherapeutics, Inc. | user2@example.com | None | 2019-11-11 | 2021-06-28 | 2022-06-28 | - | - | 2025-07-14 |
| SNS-301 Monotherapy in High Risk MDS and CMML | NCT04217720 | Sensei Biotherapeutics, Inc. | user2@example.com | None | 2020-04-01 | 2023-01-01 | 2024-01-01 | - | - | 2025-07-14 |